Beyond Air To Participate in the 2023 Cantor Global Healthcare Conference

GARDEN CITY, N.Y., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.), today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will present a corporate overview and participate in one-on-one meetings at the 2023 Cantor Global Healthcare Conference, on Wednesday, September 27^th.

2023 Cantor Global Healthcare Conference: September 26 – 28, 2023
	Title:	Beyond Air (NASDAQ: XAIR) Company Presentation
	Date & Time:	Wednesday, September 27th, at 9:10 a.m. – 9:40 a.m. ET
	Participant:	Steve Lisi, Chairman & CEO, Beyond Air
	Webcast Link:	https://wsw.com/webcast/cantor19/xair/2102100

If you are interested in requesting a 1x1 meeting at the conference, please contact your bank/conference representative.

About Beyond Air, Inc.
Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval for its first system, LungFit PH for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM). The Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ADS) and other neurological disorders. Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.